# Bioequivalence of Two Formulations of Meropenem Intravenous Injection

> **NCT02344563** · PHASE4 · COMPLETED · sponsor: **Yung Shin Pharm. Ind. Co., Ltd.** · enrollment: 14 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Meropem
- **DRUG:** Mepem

## Key facts

- **NCT ID:** NCT02344563
- **Lead sponsor:** Yung Shin Pharm. Ind. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-09
- **Final completion:** 2014-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2015-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02344563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02344563, "Bioequivalence of Two Formulations of Meropenem Intravenous Injection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02344563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*